WORLD HEALTH ORGANIZATION

NeoGenomics launches AML Express, an NGS assay for rapid genetic profiling of AML, addressing the need for faster biomarker testing and enhancing their oncology portfolio.

NKGen Biotech to present Phase 1 study results of troculeucel for Alzheimer’s disease at CTAD 2024 in Madrid.

NKGen Biotech to present Phase 1 study results of troculeucel for Alzheimer’s disease at CTAD 2024 in Madrid, Spain.

CDC to screen travelers from Rwanda for Marburg virus starting Oct. 14, routing them through Chicago O’Hare, JFK, or Washington Dulles for temperature checks and symptom assessments. Rwanda reports 56 confirmed cases, 12 deaths. No U.S. cases reported. Marburg causes hemorrhagic fever, spreads through bodily fluids, and has a high death rate.

References on Ewing sarcoma include genetic detection of t(11;22) translocation, EWS-ETS fusion type impact on disease progression, FDG-PET for staging, and role of bone marrow biopsy versus PET/CT imaging.

References discuss hepatocellular carcinoma epidemiology, chemoembolization, autophagy regulation, and fasting effects on cancer therapy.

New human H5 influenza cases in California, Marburg vaccine trial in Rwanda, and chem-bio AI model safety considerations.

FluoGuide A/S submitted a Clinical Trial Application for a phase II trial in head and neck cancer, with a live streaming event on 18 October 2024, discussing the trial design and FG001's clinical applications.

The Antibody Drug Conjugates market was valued at USD 5,475.84 Million in 2023 and is projected to reach USD 39,153.21 Million by 2032, growing at a CAGR of 24.0%. ADCs are crucial for precision cancer therapy, with over 100 in clinical trials and eight approved since 2020. Companies like Merck and Daiichi Sankyo are expanding their portfolios and geographical reach. The market is segmented by type, product, and application, with monoclonal antibodies leading. North America dominates the ADC market, driven by the U.S. due to advanced healthcare systems and research.